antibodies -online.com





anti-SIGLEC5 antibody (C-Term)

2 Images



Go to Product page

| \sim | | | | | | |
|--------|-----|---|----|----|-------------|---|
| | 1// | Д | r۱ | /1 | \triangle | ٨ |

| Overview | | |
|----------------------|--|--|
| Quantity: | 400 μL | |
| Target: | SIGLEC5 | |
| Binding Specificity: | AA 482-513, C-Term | |
| Reactivity: | Human, Mouse | |
| Host: | Rabbit | |
| Clonality: | Polyclonal | |
| Conjugate: | This SIGLEC5 antibody is un-conjugated | |
| Application: | Western Blotting (WB) | |
| Product Details | | |
| Immunogen: | This SIGLEC5 antibody is generated from rabbits immunized with a KLH conjugated synthetic | |
| | peptide between 482-513 amino acids from the C-terminal region of human SIGLEC5. | |
| Isotype: | Ig Fraction | |
| Purification: | This antibody is purified through a protein A column, followed by peptide affinity purification. | |
| Target Details | | |
| Target: | SIGLEC5 | |
| Alternative Name: | SIGLEC5 (SIGLEC5 Products) | |
| Background: | SIGLECs are members of the immunoglobulin superfamily that are expressed on the cell | |
| | surface. Most SIGLECs have one or more cytoplasmic immune receptor tyrosine-based | |
| | inhibitory motifs (ITIM). SIGLECs are typically expressed on cells of the innate immune system, | |
| | | |

with the exception of the B-cell expressed SIGLEC6. Sequence analysis predicted that the 697-amino acid SIGLEC10 protein contains a signal peptide, an N-terminal V-set Ig-like domain and four C2-set Ig-like domains, five potential N-linked glycosylation sites, a transmembrane region, and a 126-residue cytoplasmic tail with 3 putative ITIMs. Northern blot analysis detected a major 3.0-kb SIGLEC10 transcript, with highest levels in spleen, lymph node, blood leukocytes, and appendix. Little or no expression was observed in pancreas, thyroid, and testis. Flow cytometric analysis demonstrated eosinophil-specific expression of SIGLEC10, but at a lower level than that of SIGLEC8. Expression was also detected on monocytes and a CD16-positive/CD56-negative natural killer-like lymphocyte population. After sialidase treatment, which is necessary for unmasking the sialic acid-binding site on SIGLECs interacting with cell surface sialic acids, cells expressing SIGLEC10 bound to red blood cells. Immunoprecipitation analysis indicated expression of a 100- to 120-kD monomeric protein, higher than the predicted molecular mass, suggesting that SIGLEC10 is glycosylated.

| Molecular Weight: | 61 kDa |
|-------------------|--------|
| Gene ID: | 8778 |
| UniProt: | 015389 |

For WB starting dilution is: 1:1000


Application Details

Application Notes:

| Restrictions: | For Research Use only |
|--------------------|---|
| Handling | |
| Format: | Liquid |
| Concentration: | 0.5 mg/mL |
| Buffer: | Supplied in PBS with 0.09 % (W/V) sodium azide. |
| Preservative: | Sodium azide |
| Precaution of Use: | This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Storage: | 4 °C,-20 °C |
| Storage Comment: | Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to |


prolonged high temperatures.

Images



Western Blotting

Image 1. Western blot analysis in SK-BR-3 cell line lysates (35ug/lane).



Western Blotting

Image 2. Antibody is used in Western blot to detect Siglec5 in mouse liver tissue lysate.